Special Issue "Perspective of Metabolism: Potential Therapeutic Targets of Metabolic Diseases such as Obesity-Associated Diabetes, Atherosclerosis and Fatty Liver"

A special issue of Medicines (ISSN 2305-6320). This special issue belongs to the section "Endocrinology and Metabolic Disorders".

Deadline for manuscript submissions: 31 October 2021.

Special Issue Editor

Dr. Abhishek Singh
E-Mail Website
Guest Editor
Pharmacology, School of Medicine, Yale university, New Haven, Connecticut, USA
Interests: lipid and glucose metabolism; atherosclerosis; diabetes; muscle atrophy; NAFLD; NASH; obesity

Special Issue Information

Dear Colleagues,

Preclinical and clinical studies have shown that elevated levels of triglyceride-rich lipoproteins (TRL) and their remnant particles are associated with the development of type 2 diabetes (T2D), coronary atherosclerosis, and fatty liver. Under normal physiological conditions, triacylglycerol (TAG) is transported through the bloodstream in circulating TRL, including chylomicrons and very-low-density lipoproteins (VLDL). TRL is hydrolyzed into free fatty acids (FFA) and glycerol by the lipoprotein lipase (LPL) in the capillary beds of many tissues, especially adipose, cardiac, and skeletal muscle where LPL releases the TAGs for intracellular storage or energy production.

The imbalance between dyslipidemia (high levels of circulating TAGs and cholesterol) and ectopic lipid accumulation is critical in metabolic homeostasis. While reducing circulating lipids could help to prevent cardiovascular diseases such as atherosclerosis, excessive accumulation of lipids in tissues can lead to lipotoxicity and insulin resistance (IR). Therefore, the management of the serum lipoprotein profile could be an effective potential therapeutic target for the treatment of metabolic diseases. For this Special Issue, we invite articles related to a metabolic pathway based on lipid and glucose metabolism that reveal therapeutic targets against cardio-metabolic disease.

Dr. Abhishek Singh
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • obesity
  • diabetes
  • atherosclerosis
  • muscle atrophy
  • liver disease
  • nonalcoholic fatty liver disease (NAFLD)
  • nonalcoholic steatohepatitis (NASH)
  • therapies
  • lipoprotein-lipid metabolism
  • glucose homeostasis
  • cardiometabolism

Published Papers

This special issue is now open for submission.
Back to TopTop